Over 50 million individuals worldwide suffer from epilepsy, a neurological condition marked by spontaneous seizures. A major clinical problem is its chronic nature and long-term predisposition for seizures. Antiepileptic drugs (AEDs) during pregnancy provide a major clinical issue since they have to strike a balance between the growing fetus's possible health concerns and the mother's capacity to control seizures. It is important to consider teratogenecity, or the fetus's susceptibility to congenital defects. Mucuna pruriens (MP), a tropical herb with noteworthy pharmacological characteristics, has being studied for possible epilepsy treatment benefits. L-DOPA, an antioxidant and neuroprotective molecule that functions as a precursor to dopamine and modifies dopaminergic neurotransmission is one of the bioactive chemicals obtained from MP. Preclinical studies have demonstrated that MP can reduce seizure frequency, lower seizure severity, and raise seizure threshold. Main body of abstract The goal of the current study was to evaluate the neurobehavioral activity of Mucuna pruriens in an experimental rat pup model by means of motor function tests, in comparison to the standard drug Lamotrigine (20 mg/kg) and control (Normal Saline). This study investigates safer substitutes that can be supplied to expectant mothers or used as an addition to current therapies that may lessen teratogenecity. Conclusion Assessing the Mucuna pruriens extract to the usual medication used in the experimental paradigm, notable improvements were seen in the motor and behavioral domains